Parkinson Disease Psychosis
📧 Sign up to get email alerts when something new happens for Parkinson Disease Psychosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-01-22FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)
The FDA approved a supplemental application for Nuplazid (pimavanserin tartrate) from Acadia Pharmaceuticals Inc. The action concerns a supp…
-
FDA approval · 2024-01-16FDA Approved: PIMAVANSERIN — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original Abbreviated New Drug Application for Pimavanserin (Pimavanserin) by Novadoz Pharmaceuticals LLC, authorizing a gen…
-
FDA approval · 2023-09-15FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)
FDA approved a supplemental application for Nuplazid (pimavanserin tartrate) submitted by Acadia Pharmaceuticals Inc. This action updates th…
-
FDA approval · 2020-11-23FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)
The FDA approved a supplemental application for Nuplazid (pimavanserin tartrate) submitted by Acadia Pharmaceuticals Inc., updating the labe…
-
FDA approval · 2019-05-10FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)
The FDA approved a supplemental application for NUPLAZID (pimavanserin tartrate) submitted by Acadia Pharmaceuticals Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-05-10FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)
The FDA approved a supplemental application for NUPLAZID (pimavanserin tartrate) from Acadia Pharmaceuticals Inc. The action represents an a…
-
FDA approval · 2019-03-04FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)
The FDA approved a supplemental NDA for NUPLAZID (pimavanserin tartrate) submitted by Acadia Pharmaceuticals.
-
FDA approval · 2019-03-04FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)
The FDA approved a supplemental application for NUPLAZID (pimavanserin tartrate) submitted by Acadia Pharmaceuticals, signaling a labeling u…
-
FDA approval · 2018-06-28FDA Approved: NUPLAZID — Original Application (Acadia Pharmaceuticals Inc.)
FDA approved NUPLAZID (pimavanserin tartrate) for the first time, marking the drug's original approval for Parkinson disease psychosis.
-
CLINICAL_TRIALS approval · 2017-04-18Clinical Trial Update: Expanded Access of Pimavanserin for Patients With PD Psychosis
Expanded access for Pimavanserin (Nuplazid) in Parkinson's disease psychosis is noted, with the status indicating approval for marketing.
-
FDA approval · 2016-04-29FDA Approved: NUPLAZID — Original Application (Acadia Pharmaceuticals Inc.)
The FDA approved Nuplazid (pimavanserin tartrate) from Acadia Pharmaceuticals in its original NDA, for the treatment of hallucinations and d…